Han Lianxiu, Wang Zilong, Kang Luyang, Cui Xiaoling, Li Yi, Yin Huafa, Gao Yufeng, Li Jiabin
Department of Infectious Diseases, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Division of Life Science and Medicine, Department of Infectious Diseases, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, Anhui, China.
Sci Rep. 2025 Apr 22;15(1):13873. doi: 10.1038/s41598-025-86555-1.
Among the factors influencing relapse after clinical cure of chronic hepatitis B(CHB). There is no standardization of baseline HBsAg levels and end-of-treatment HBsAb levels. This multicenter, retrospective study enrolled 136 patients who achieved functional cure from June 2019 to December 2023, and a total of 48 weeks of follow-up was conducted after treatment cessation according to the CHB guidelines. Baseline characteristics of patients were analyzed using univariates. Multifactorial logistic regression was used to analyze the different levels of HBsAg at baseline and HBsAb at the end of treatment in CHB recurrence. The working characteristic curve of the subject was constructed and observed by the column line graphical prediction model. Our data showed the cumulative recurrence rate using Kaplan-Meier survival analysis. At baseline, the level of HBsAg was significantly greater in the group with recurrence than in the group without recurrence (P = 0.038). At EOT, HBsAb levels were lower in the relapsed group than in the nonrelapsed group (P = 0.014). Multivariate logistic regression analysis revealed that a baseline serum HBsAg concentration ≥ 100 IU/mL was a risk factor for recurrence, and an EOT serum HBsAb concentration ≥ 500 mIU/mL was a protective factor for recurrence. Kaplan-Meier survival analysis showed relapse rates of 3.8% and 12.2% for HBsAg ≤ 100 IU/mL at baseline and HBsAb ≥ 500 mIU/mL at the end of treatment, respectively. Functionally cured patients with CHB when baseline HBsAg ≤ 100 IU/mL and HBsAb ≥ 500 mIU/mL at the end of treatment have a low relapse rate.
在影响慢性乙型肝炎（CHB）临床治愈后复发的因素中。基线HBsAg水平和治疗结束时HBsAb水平尚无标准化。这项多中心回顾性研究纳入了2019年6月至2023年12月实现功能性治愈的136例患者，并根据CHB指南在停药后进行了共48周的随访。使用单变量分析患者的基线特征。采用多因素逻辑回归分析CHB复发时基线HBsAg的不同水平和治疗结束时HBsAb的不同水平。通过列线图预测模型构建并观察受试者工作特征曲线。我们的数据显示了使用Kaplan-Meier生存分析的累积复发率。在基线时，复发组的HBsAg水平显著高于未复发组（P = 0.038）。在治疗结束时，复发组的HBsAb水平低于未复发组（P = 0.014）。多变量逻辑回归分析显示，基线血清HBsAg浓度≥100 IU/mL是复发的危险因素，治疗结束时血清HBsAb浓度≥500 mIU/mL是复发的保护因素。Kaplan-Meier生存分析显示，基线时HBsAg≤100 IU/mL且治疗结束时HBsAb≥500 mIU/mL的CHB功能性治愈患者的复发率分别为3.8%和12.2%。当基线HBsAg≤100 IU/mL且治疗结束时HBsAb≥500 mIU/mL时，CHB功能性治愈患者的复发率较低。
